UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30, 2019~~March 31, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 1-2189

ABBOTT LABORATORIES

An Illinois Corporation		I.R.S. Employer Identification No.
		36-0698440

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

Telephone: (224) 667-6100

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Shares, Without Par Value		ABT		New York Stock Exchange Chicago Stock Exchange, Inc.

Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large Accelerated Filer	☒	Accelerated Filer	☐
Non-Accelerated Filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~September 30, 2019,~~March 31, 2020, Abbott Laboratories had ~~1,768,455,705~~1,768,845,326 common shares without par value outstanding.

Table of Contents

Abbott Laboratories

Table of Contents

	~~Page~~

Part I - Financial Information
	Page
Item 1. Financial Statements and Supplementary Data

Condensed Consolidated Statement of Earnings	3
Condensed Consolidated Statement of Comprehensive Income	4
Condensed Consolidated Balance Sheet	5
Condensed Consolidated Statement of Shareholders’ Investment	6
Condensed Consolidated Statement of Cash Flows	87
Notes to the Condensed Consolidated Financial Statements	98

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	2117

Item 4. Controls and Procedures	2622

Part II - Other Information

Item 1. Legal Proceedings	2622

Item 1A. Risk Factors	22

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	2723

Item 6. Exhibits	2824

Signature	2925

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited)

(dollars in millions except per share data; shares in thousands)


	Three Months Ended September 30				Nine Months Ended September 30				Three Months Ended March 31
	2019		2018		2019		2018		2020		2019
Net sales	$	8,076	$	7,656	$	23,590	$	22,813	$	7,726	$	7,535

Cost of products sold, excluding amortization of intangible assets		3,358		3,166		9,797		9,515		3,281		3,160
Amortization of intangible assets		484		544		1,453		1,690		561		486
Research and development		596		574		1,845		1,738		578		672
Selling, general and administrative		2,440		2,377		7,352		7,385		2,548		2,478
Total operating cost and expenses		6,878		6,661		20,447		20,328		6,968		6,796

Operating earnings		1,198		995		3,143		2,485		758		739

Interest expense		167		203		506		640		139		171
Interest (income)		(24)		(22)		(69)		(71)		(18)		(23)
Net foreign exchange (gain) loss		7		11		9		2		5		6
Net loss on extinguishment of debt		—		67		—		81
Other (income) expense, net		(55)		18		(140)		(93)		(1)		(47)
Earnings from continuing operations before taxes		1,103		718		2,837		1,926
Taxes on earnings from continuing operations		143		166		199		247
Earnings from continuing operations before tax										633		632
Tax expense (benefit) on earnings from continuing operations										89		(40)
Earnings from continuing operations		960		552		2,638		1,679		544		672

Earnings from discontinued operations, net of tax		—		11		—		35		20		—

Net Earnings	$	960	$	563	$	2,638	$	1,714	$	564	$	672

Basic Earnings Per Common Share —
Continuing operations	$	0.54	$	0.31	$	1.48	$	0.95	$	0.31	$	0.38
Discontinued operations		—		0.01		—		0.02		0.01		—
Net earnings	$	0.54	$	0.32	$	1.48	$	0.97	$	0.32	$	0.38

Diluted Earnings Per Common Share —
Continuing operations	$	0.53	$	0.31	$	1.47	$	0.94	$	0.30	$	0.38
Discontinued operations		—		0.01		—		0.02		0.01		—
Net earnings	$	0.53	$	0.32	$	1.47	$	0.96	$	0.31	$	0.38

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share		1,771,521		1,759,585		1,767,985		1,757,018		1,768,901		1,763,278
Dilutive Common Stock Options		12,646		12,095		12,818		11,692		11,677		13,295
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options		1,784,167		1,771,680		1,780,803		1,768,710		1,780,578		1,776,573

Outstanding Common Stock Options Having No Dilutive Effect		61		44		61		44		4,035		4,011

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Comprehensive Income

(Unaudited)

(dollars in millions)


	Three Months Ended September 30				Nine Months Ended September 30				Three Months Ended March 31
	2019		2018		2019		2018		2020		2019
Net Earnings	$	960	$	563	$	2,638	$	1,714	$	564	$	672
Foreign currency translation gain (loss) adjustments		(478)		(153)		(265)		(1,179)		(1,144)		122
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $7 and $21 in 2019 and $16 and $48 in 2018		31		22		80		106
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $23 and $8 in 2019 and $16 and $44 in 2018		49		35		8		121
Other comprehensive (loss)		(398)		(96)		(177)		(952)
Comprehensive Income	$	562	$	467	$	2,461	$	762
Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $15 in 2020 and $7 in 2019										57		23
Net gains (losses) for derivative instruments designated as cash flow hedges, net of taxes of $48 in 2020 and $(8) in 2019										166		(29)
Other comprehensive income (loss)										(921)		116
Comprehensive Income (Loss)									$	(357)	$	788


	September 30,		December 31,		March 31,		December 31,
	2019		2018		2020		2019
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments	$	(5,177)	$	(4,912)	$	(6,068)	$	(4,924)
Net actuarial (losses) and prior service (costs) and credits		(2,646)		(2,726)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other		60		52
Accumulated other comprehensive income (loss)	$	(7,763)	$	(7,586)
Net actuarial (losses) and prior service (cost) and credits						(3,483)		(3,540)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges						165		(1)
Accumulated Other Comprehensive Income (Loss)					$	(9,386)	$	(8,465)

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Balance Sheet

(Unaudited)

(dollars in millions)


	September 30,		December 31,		March 31,		December 31,
	2019		2018		2020		2019
Assets
Current Assets:
Cash and cash equivalents	$	4,091	$	3,844	$	3,377	$	3,860
Short-term investments		244		242		291		280
Trade receivables, less allowances of $354 in 2019 and $314 in 2018		5,450		5,182
Trade receivables, less allowances of $389 in 2020 and $384 in 2019						5,292		5,425
Inventories:
Finished products		2,846		2,407		2,873		2,784
Work in process		584		499		615		560
Materials		962		890		1,080		972
Total inventories		4,392		3,796		4,568		4,316
Prepaid expenses and other receivables		1,942		1,568		1,970		1,786
Total Current Assets		16,119		14,632		15,498		15,667
Investments		874		897		790		883
Property and equipment, at cost		16,343		15,706		16,707		16,799
Less: accumulated depreciation and amortization		8,518		8,143		8,800		8,761
Net property and equipment		7,825		7,563		7,907		8,038
Intangible assets, net of amortization		17,465		18,942		16,265		17,025
Goodwill		23,046		23,254		22,927		23,195
Deferred income taxes and other assets		3,210		1,885		3,390		3,079
	$	68,539	$	67,173	$	66,777	$	67,887
Liabilities and Shareholders’ Investment
Current Liabilities:
Short-term borrowings	$	204	$	200	$	204	$	201
Trade accounts payable		3,029		2,975		3,181		3,252
Salaries, wages and commissions		1,258		1,182		949		1,237
Other accrued liabilities		4,112		3,780		4,408		4,035
Dividends payable		567		563		637		635
Income taxes payable		67		305		165		226
Current portion of long-term debt		1,254		7		1,264		1,277
Total Current Liabilities		10,491		9,012		10,808		10,863
Long-term debt		17,639		19,359		16,804		16,661
Post-employment obligations, deferred income taxes and other long-term liabilities		8,390		8,080		8,738		9,062
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, 1 dollar par value Authorized — 1,000,000 shares, NaN issued		—		—		—		—
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2019: 1,976,705,285; 2018: 1,971,189,465		23,771		23,512
Common shares held in treasury, at cost — Shares: 2019: 208,249,580; 2018: 215,570,043		(9,631)		(9,962)
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2020: 1,978,112,501 ; 2019: 1,976,855,085						23,731		23,853
Common shares held in treasury, at cost — Shares: 2020: 209,267,175 ; 2019: 214,351,838						(9,913)		(10,147)
Earnings employed in the business		25,440		24,560		25,786		25,847
Accumulated other comprehensive income (loss)		(7,763)		(7,586)		(9,386)		(8,465)
Total Abbott Shareholders’ Investment		31,817		30,524		30,218		31,088
Noncontrolling Interests in Subsidiaries		202		198		209		213
Total Shareholders’ Investment		32,019		30,722		30,427		31,301
	$	68,539	$	67,173	$	66,777	$	67,887

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Shareholders’ Investment

(Unaudited)

(in millions except shares and per share data)

Three Months Ended September 30


2019

2018
Common Shares:




Balance at June 30




Shares: 2019: 1,976,248,129; 2018: 1,969,575,366

$
23,665

$
23,317
Issued under incentive stock programs




Shares: 2019: 457,156; 2018: 1,015,106

18

33
Share-based compensation

93

83
Issuance of restricted stock awards

(5)

(5)
Balance at September 30

Shares: 2019: 1,976,705,285; 2018: 1,970,590,472

$
23,771

$
23,428

Common Shares Held in Treasury:




Balance at June 30

Shares: 2019: 208,850,514; 2018: 215,256,082

$
(9,659)

$
(9,907)
Issued under incentive stock programs

Shares: 2019: 605,458; 2018: 1,002,519

28

49
Purchased

Shares: 2019: 4,524; 2018: 3,877

—

—
Balance at September 30

Shares: 2019: 208,249,580; 2018: 214,257,440

$
(9,631)

$
(9,858)

Earnings Employed in the Business:




Balance at June 30

$
25,045

$
24,080
Net earnings

960

563
Cash dividends declared on common shares (per share — 2019: $0.32; 2018: $0.28)

(570)

(495)
Effect of common and treasury share transactions

5

(4)
Balance at September 30

$
25,440

$
24,144

Accumulated Other Comprehensive Income (Loss):




Balance at June 30

$
(7,365)

$
(6,913)
Other comprehensive income (loss)

(398)

(96)
Balance at September 30

$
(7,763)

$
(7,009)

Noncontrolling Interests in Subsidiaries:




Balance at June 30

$
208

$
197
Noncontrolling Interests’ share of income, business combinations, net of distributions
and share repurchases

(6)

(4)
Balance at September 30

$
202

$
193

~~The accompanying notes to condensed consolidated financial statements are an integral part of this statement.~~

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Condensed Consolidated Statement of Shareholders’ Investment~~

~~(Unaudited)~~

~~(in millions except shares and per share data)~~


	Nine Months Ended September 30				Three Months Ended March 31
	2019		2018		2020		2019
Common Shares:
Balance at January 1
Shares: 2019: 1,971,189,465; 2018: 1,965,908,188	$	23,512	$	23,206
Shares: 2020: 1,976,855,085; 2019: 1,971,189,465					$	23,853	$	23,512
Issued under incentive stock programs
Shares: 2019: 5,515,820; 2018: 4,682,284		205		145
Shares: 2020: 1,257,416; 2019: 2,283,041						53		76
Share-based compensation		436		398		245		237
Issuance of restricted stock awards		(382)		(321)		(420)		(364)
Balance at September 30
Shares: 2019: 1,976,705,285; 2018: 1,970,590,472	$	23,771	$	23,428
Balance at March 31
Shares: 2020: 1,978,112,501; 2019: 1,973,472,506					$	23,731	$	23,461

Common Shares Held in Treasury:
Balance at January 1
Shares: 2019: 215,570,043; 2018: 222,305,719	$	(9,962)	$	(10,225)
Shares: 2020: 214,351,838; 2019: 215,570,043					$	(10,147)	$	(9,962)
Issued under incentive stock programs
Shares: 2019: 7,591,844; 2018: 8,296,855		352		382
Shares: 2020: 5,333,626; 2019: 6,544,927						253		303
Purchased
Shares: 2019: 271,381; 2018: 248,576		(21)		(15)
Balance at September 30
Shares: 2019: 208,249,580; 2018: 214,257,440	$	(9,631)	$	(9,858)
Shares: 2020: 248,963; 2019: 266,128						(19)		(20)
Balance at March 31
Shares: 2020: 209,267,175; 2019: 209,291,244					$	(9,913)	$	(9,679)

Earnings Employed in the Business:
Balance at January 1	$	24,560	$	23,978	$	25,847	$	24,560
Impact of adoption of new accounting standards		—		15
Impact of adoption of new accounting standard						(5)		—
Net earnings		2,638		1,714		564		672
Cash dividends declared on common shares (per share — 2019: $0.96; 2018: $0.84)		(1,706)		(1,483)
Cash dividends declared on common shares (per share — 2020: $0.36; 2019: $0.32)						(641)		(568)
Effect of common and treasury share transactions		(52)		(80)		21		(51)
Balance at September 30	$	25,440	$	24,144
Balance at March 31					$	25,786	$	24,613

Accumulated Other Comprehensive Income (Loss):
Balance at January 1	$	(7,586)	$	(6,062)	$	(8,465)	$	(7,586)
Impact of adoption of new accounting standard		—		5
Other comprehensive income (loss)		(177)		(952)		(921)		116
Balance at September 30	$	(7,763)	$	(7,009)
Balance at March 31					$	(9,386)	$	(7,470)

Noncontrolling Interests in Subsidiaries:
Balance at January 1	$	198	$	201	$	213	$	198
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases		4		(8)		(4)		6
Balance at September 30	$	202	$	193
Balance at March 31					$	209	$	204

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Cash Flows

(Unaudited)

(dollars in millions)


	Nine Months Ended September 30				Three Months Ended March 31
	2019		2018		2020		2019
Cash Flow From (Used in) Operating Activities:
Net earnings	$	2,638	$	1,714	$	564	$	672
Adjustments to reconcile net earnings to net cash from operating activities -
Depreciation		805		825		267		267
Amortization of intangible assets		1,453		1,690		561		486
Share-based compensation		434		396		233		226
Amortization of inventory step-up		—		32
Trade receivables		(357)		(280)		(104)		(170)
Inventories		(730)		(450)		(437)		(286)
Other, net		(523)		608		(369)		(483)
Net Cash From Operating Activities		3,720		4,535		715		712

Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment		(1,204)		(927)		(360)		(335)
Acquisitions of businesses and technologies, net of cash acquired		(171)		(43)		—		(78)
Proceeds from business dispositions		48		48
Sales (purchases) of other investment securities, net		(22)		(23)		(36)		2
Other		23		85		3		15
Net Cash (Used in) Investing Activities		(1,326)		(860)		(393)		(396)

Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other		52		22		51		13
Proceeds from issuance of long-term debt		—		4,011
Repayments of long-term debt		(523)		(8,279)		(1)		(500)
Purchases of common shares		(222)		(134)		(236)		(217)
Proceeds from stock options exercised		291		244		89		127
Dividends paid		(1,702)		(1,479)		(638)		(565)
Net Cash (Used in) Financing Activities		(2,104)		(5,615)		(735)		(1,142)

Effect of exchange rate changes on cash and cash equivalents		(43)		(98)		(70)		4

Net Increase (Decrease) in Cash and Cash Equivalents		247		(2,038)
Net Decrease in Cash and Cash Equivalents						(483)		(822)
Cash and Cash Equivalents, Beginning of Year		3,844		9,407		3,860		3,844
Cash and Cash Equivalents, End of Period	$	4,091	$	7,369	$	3,377	$	3,022

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

~~September 30, 2019~~March 31, 2020

(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, ~~2018.~~2019. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

Note 2 — New Accounting Standards

Recently Adopted Accounting Standards

In ~~February~~June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) ~~2016-02,~~ ~~Leases~~, which requires lessees to measure and recognize a lease asset and liability on the balance sheet for most leases, including operating leases. Abbott adopted the new standard as of January 1, 2019 using the modified retrospective approach and applied the standard’s transition provisions as of January 1, 2019. As a result, no changes were made to the December 31, 2018 Consolidated Balance Sheet. Abbott elected to apply the package of practical expedients related to transition. These practical expedients allowed Abbott to carry forward its historical assessments of whether any existing contracts are or contain leases, the lease classification for each lease existing at January 1, 2019, and whether any initial direct costs for such leases qualified for capitalization.

The new lease accounting standard does not have a material impact on the amounts reported in the Condensed Consolidated Statement of Earnings but does have a material impact on the amounts reported in the Condensed Consolidated Balance Sheet. Adoption of the new standard resulted in the recording of approximately $850 million of new right of use (ROU) assets and additional liabilities for operating leases on the Condensed Consolidated Balance Sheet as of January 1, 2019.

~~Recent Accounting Standards Not Yet Adopted~~

~~In June 2016, the FASB issued ASU~~ 2016-13, Financial Instruments – Credit Losses, which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. Abbott adopted the standard on January 1, 2020 and recorded a cumulative adjustment that was not significant to Earnings employed in the business in the Condensed Consolidated Balance Sheet.

Recent Accounting Standards Not Yet Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The ~~new~~ standard ~~will be~~becomes effective for Abbott atin the ~~beginning~~first quarter of ~~2020, with~~2021 and early adoption is permitted. Abbott ~~is currently assessing the impact~~does not expect adoption of this new standard to have a material impact on its condensed consolidated financial statements.

Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has 4 reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and ~~Cardiovascular and Neuromodulation Products. Diabetes Care is a non-reportable segment and is included in Other.~~Medical Devices.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

~~September 30, 2019~~March 31, 2020

(Unaudited)

The following ~~tables provide detail~~table provides revenues by sales category:


	Three Months Ended September 30, 2019						Three Months Ended September 30, 2018						Three Months Ended March 31, 2020						Three Months Ended March 31, 2019
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	891	$	891	$	—	$	866	$	866	$	—	$	813	$	813	$	—	$	752	$	752
Other		—		321		321		—		293		293		—		231		231		—		240		240
Total		—		1,212		1,212		—		1,159		1,159		—		1,044		1,044		—		992		992

Nutritionals —
Pediatric Nutritionals		478		566		1,044		459		580		1,039		518		571		1,089		453		576		1,029
Adult Nutritionals		310		520		830		315		484		799		294		521		815		294		469		763
Total		788		1,086		1,874		774		1,064		1,838		812		1,092		1,904		747		1,045		1,792

Diagnostics —
Core Laboratory		272		905		1,177		249		837		1,086		267		722		989		249		812		1,061
Molecular		35		76		111		37		84		121		65		74		139		40		68		108
Point of Care		112		32		144		106		30		136		103		35		138		109		26		135
Rapid Diagnostics		283		194		477		274		207		481		368		192		560		326		211		537
Total		702		1,207		1,909		666		1,158		1,824		803		1,023		1,826		724		1,117		1,841

Cardiovascular and Neuromodulation —
Medical Devices -
Rhythm Management		265		273		538		272		261		533		228		246		474		252		262		514
Electrophysiology		185		242		427		169		212		381		164		224		388		174		231		405
Heart Failure		136		50		186		111		41		152		152		51		203		143		41		184
Vascular		251		446		697		284		436		720		230		395		625		266		443		709
Structural Heart		158		190		348		126		179		305		136		182		318		136		188		324
Neuromodulation		165		39		204		172		40		212		137		40		177		152		41		193
Diabetes Care														186		566		752		152		414		566
Total		1,160		1,240		2,400		1,134		1,169		2,303		1,233		1,704		2,937		1,275		1,620		2,895

Other		184		497		681		133		399		532		8		7		15		8		7		15
Total	$	2,834	$	5,242	$	8,076	$	2,707	$	4,949	$	7,656	$	2,856	$	4,870	$	7,726	$	2,754	$	4,781	$	7,535

Nine Months Ended September 30, 2019

Nine Months Ended September 30, 2018
(in millions)

U.S.

Int’l

Total

U.S.

Int’l

Total
Established Pharmaceutical Products —












Key Emerging Markets

$
—

$
2,496

$
2,496

$
—

$
2,525

$
2,525
Other

—

816

816

—

807

807
Total

—

3,312

3,312

—

3,332

3,332

Nutritionals —












Pediatric Nutritionals

1,406

1,718

3,124

1,376

1,708

3,084
Adult Nutritionals

915

1,502

2,417

937

1,431

2,368
Total

2,321

3,220

5,541

2,313

3,139

5,452

Diagnostics —












Core Laboratory

793

2,614

3,407

725

2,508

3,233
Molecular

113

213

326

114

247

361
Point of Care

334

90

424

324

92

416
Rapid Diagnostics

881

617

1,498

855

669

1,524
Total

2,121

3,534

5,655

2,018

3,516

5,534

Cardiovascular and Neuromodulation —












Rhythm Management

790

810

1,600

843

824

1,667
Electrophysiology

549

713

1,262

499

645

1,144
Heart Failure

428

143

571

342

126

468
Vascular

787

1,349

2,136

854

1,355

2,209
Structural Heart

446

578

1,024

353

560

913
Neuromodulation

485

124

609

513

133

646
Total

3,485

3,717

7,202

3,404

3,643

7,047

Other

511

1,369

1,880

349

1,099

1,448
Total

$
8,438

$
15,152

$
23,590

$
8,084

$
14,729

$
22,813

Note: Insertable Cardiac Monitor (ICM) sales, which had previously been reported in Electrophysiology, are now included in Rhythm Management. Historic periods have been adjusted to reflect this change.

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2019~~

~~(Unaudited)~~

Remaining Performance Obligations

As of ~~September 30, 2019,~~March 31, 2020, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately ~~$3.2~~$3.4 billion in the Diagnostics segment and approximately ~~$350~~$400 million in the ~~Cardiovascular and Neuromodulation~~Medical Devices segment. Abbott expects to recognize revenue on approximately 60 percent of these remaining performance obligations over the next 24 months, approximately 1617 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at ~~their~~the net ~~realizable value.~~amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the ~~Cardiovascular and Neuromodulation~~Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2020

(Unaudited)

Changes in the contract liabilities during the period are as follows:

(in millions)

Contract Liabilities:

Balance at December 31, 2018

$
259
Unearned revenue from cash received during the period

285
Revenue recognized that was included in contract liability balance at beginning of period

(249)
Balance at September 30, 2019

$
295


(in millions)
Contract Liabilities
Balance at December 31, 2019	$	294
Unearned revenue from cash received during the period		105
Revenue recognized related to contract liability balance		(94)
Balance at March 31, 2020	$	305

Note 4 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares for the three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ were ~~$954~~$541 million and ~~$548~~$668 million, ~~respectively, and for the nine months ended September 30, 2019 and 2018 were $2.622 billion and $1.669 billion,~~ respectively. Net earnings allocated to common shares for the three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ were ~~$954~~$561 million and ~~$560~~$668 million, ~~respectively, and for the nine months ended September 30, 2019 and 2018 were $2.622 billion and $1.704 billion,~~ respectively.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first ~~nine~~three months of ~~2019~~2020 includes ~~$337~~$320 million of pension contributions and the payment of cash taxes of approximately ~~$775~~$125 million. The first ~~nine~~three months of ~~2018~~2019 includes $313 million of pension contributions and the ~~favorable impact~~payment of ~~improvements~~cash taxes of approximately $185 million.

Earnings from discontinued operations, net of tax, in ~~working capital management,~~the first quarter of 2020 include the recognition of $20 million of tax benefits as ~~well as~~a result of the ~~effect~~resolution of ~~non-cash charges~~various tax positions related to the ~~impairment~~previous sale of ~~certain assets~~a business that was reported as a discontinued operation.

The following summarizes the activity for the first three months of 2020 related to the allowance for doubtful accounts as of March 31, 2020:


(in millions)
Allowance for Doubtful Accounts
Balance at December 31, 2019	$	228
Impact of adopting ASU 2016-13		7
Provisions/charges to income		21
Amounts charged off and other deductions		(15)
Balance at March 31, 2020	$	241

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivables. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts including the ~~accrual~~aging of ~~certain debt extinguishment costs.~~the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.

The components of long-term investments as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018~~2019 are as follows:


	September 30,		December 31,		March 31,		December 31,
(in millions)	2019		2018		2020		2019
Long-term Investments:
Long-term Investments
Equity securities	$	830	$	856	$	741	$	836
Other		44		41		49		47
Total	$	874	$	897	$	790	$	883

Abbott’s long-term investments as of March 31, 2020, declined versus the balance as of December 31, 2019, due in part to the impairment of an investment for approximately $50 million.

1110

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

~~September 30, 2019~~March 31, 2020

(Unaudited)

Abbott's equity securities as of ~~September 30, 2019,~~March 31, 2020, include approximately ~~$330~~$289 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott also holds certain investments as of ~~September 30, 2019~~March 31, 2020 with a carrying value of approximately ~~$335~~$275 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately ~~$155~~$162 million that do not have a readily determinable fair value. The ~~$155~~$162 million carrying value includes cumulative unrealized gains of approximately $50 million.

In the first quarter of 2019, in conjunction with the acquisition of Cephea Valve Technologies, Inc., Abbott acquired a research & development (R&D) asset valued at $102 million, which was immediately expensed. The $102 million of expense was recorded in the R&D line of Abbott's Condensed Consolidated Statement of Earnings.

Note 5 — Changes in Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended September 30

Cumulative Gains

Cumulative

(Losses) on

Net Actuarial

Unrealized Gains

Derivative

Cumulative Foreign

(Losses) and Prior

(Losses) on

Instruments

Currency Translation

Service (Costs)

Marketable Equity

Designated as
(in millions)

Adjustments

and Credits

Securities

Cash Flow Hedges


2019

2018

2019

2018

2019

2018

2019

2018
Balance at June 30

$
(4,699)

$
(4,478)

$
(2,677)

$
(2,437)

$
—

$
—

$
11

$
2
Other comprehensive income (loss) before reclassifications

(478)

(153)

7

—

—

—

67

10
Amounts reclassified from accumulated other comprehensive income

—

—

24

22

—

—

(18)

25
Net current period comprehensive income (loss)

(478)

(153)

31

22

—

—

49

35
Balance at September 30

$
(5,177)

$
(4,631)

$
(2,646)

$
(2,415)

$
—

$
—

$
60

$
37


																	Three Months Ended March 31
	Nine Months Ended September 30																								Cumulative Gains
													Cumulative Gains												(Losses) on
									Cumulative				(Losses) on								Net Actuarial				Derivative
					Net Actuarial				Unrealized Gains				Derivative				Cumulative Foreign				(Losses) and Prior				Instruments
	Cumulative Foreign				(Losses) and Prior				(Losses) on				Instruments				Currency Translation				Service (Costs)				Designated as
	Currency Translation				Service (Costs)				Marketable Equity				Designated as				Adjustments				and Credits				Cash Flow Hedges
(in millions)	Adjustments				and Credits				Securities				Cash Flow Hedges				2020		2019		2020		2019		2020		2019
	2019		2018		2019		2018		2019		2018		2019		2018
Balance at December 31 , 2018 and 2017	$	(4,912)	$	(3,452)	$	(2,726)	$	(2,521)	$	—	$	(5)	$	52	$	(84)
Impact of adoption of new accounting standard		—		—		—		—		—		5		—		—
Balance at January 1																	$	(4,924)	$	(4,912)	$	(3,540)	$	(2,726)	$	(1)	$	52
Other comprehensive income (loss) before reclassifications		(265)		(1,179)		9		—		—		—		48		38		(1,144)		122		7		(1)		176		(17)
Amounts reclassified from accumulated other comprehensive income		—		—		71		106		—		—		(40)		83		—		—		50		24		(10)		(12)
Net current period comprehensive income (loss)		(265)		(1,179)		80		106		—		—		8		121		(1,144)		122		57		23		166		(29)
Balance at September 30	$	(5,177)	$	(4,631)	$	(2,646)	$	(2,415)	$	—	$	—	$	60	$	37
Balance at March 31																	$	(6,068)	$	(4,790)	$	(3,483)	$	(2,703)	$	165	$	23

Reclassified amounts for foreign currency translation are recorded in the Condensed Consolidated Statement of Earnings as Net foreign exchange (gain) ~~loss~~loss; and amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 1312 for additional details.

Note 6 — Goodwill and Intangible Assets

The total amount of goodwill reported was $22.9 billion at March 31, 2020 and $23.2 billion at December 31, 2019. Foreign currency translation adjustments decreased goodwill by approximately $268 million in the first three months of 2020. The amount of goodwill related to reportable segments at March 31, 2020 was $2.8 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.6 billion for the Diagnostic Products segment, and $16.1 billion for the Medical Devices segment. There was 0 reduction of goodwill relating to impairments in the first three months of 2020.

The gross amount of amortizable intangible assets, primarily product rights and technology was $27.3 billion as of March 31, 2020 and $27.6 billion as of December 31, 2019, and accumulated amortization was $12.3 billion as of March 31, 2020 and $11.9 billion as of December 31, 2019. Foreign currency translation adjustments decreased intangible assets by $204 million for the first three months of 2020. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.1 billion in 2020, $2.0 billion in 2021, 2022, and 2023 and $1.9 billion in 2024.

Indefinite-lived intangible assets, which relate to in-process R&D acquired in a business combination, were approximately $1.2 billion and $1.3 billion as of March 31, 2020 and December 31, 2019, respectively.

1211

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

~~September 30, 2019~~March 31, 2020

(Unaudited)

~~Note 6 — Goodwill and Intangible Assets~~

The total amount of goodwill reported was $23.0 billion at September 30, 2019 and $23.3 billion at December 31, 2018. Foreign currency translation adjustments decreased goodwill by approximately $252 million during the first nine months of 2019. The amount of goodwill related to reportable segments at September 30, 2019 was $3.0 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.7 billion for the Diagnostic Products segment, and $15.2 billion for the Cardiovascular and Neuromodulation Products segment. There was 0 reduction of goodwill relating to impairments in the first nine months of 2019.

The gross amount of amortizable intangible assets, primarily product rights and technology was $25.1 billion as of September 30, 2019 and $25.7 billion as of December 31, 2018, and accumulated amortization was $11.2 billion as of September 30, 2019 and $10.4 billion as of December 31, 2018. Foreign currency translation adjustments decreased intangible assets by approximately $110 million during the first nine months of 2019. Abbott’s estimated annual amortization expense for intangible assets is approximately $1.9 billion in 2019, $2.1 billion in 2020, $2.0 billion in 2021, $2.0 billion in 2022 and $2.0 billion in 2023.

Indefinite-lived intangible assets, which relate to in-process research and development acquired in a business combination, were approximately $3.6 billion as of September 30, 2019 and December 31, 2018.

Note 7 — Restructuring Plans

From 2017 to ~~2019,~~2020, Abbott management approved restructuring plans as part of the integration of the acquisitions of St. Jude Medical into the ~~Cardiovascular and Neuromodulation~~Medical Devices segment, and Alere Inc. (Alere) into the ~~Diagnostics~~Diagnostic Products segment, in order to leverage economies of scale and reduce costs. In the first ~~nine~~three months of ~~2019,~~2020, charges of ~~$66~~$9 million were recognized, of which ~~$18~~$3 million is recorded in Cost of products sold, $4$1 million is recorded in Research and development and ~~$44~~$5 million as Selling, general and administrative expense. The following summarizes the activity for the first ~~nine~~three months of ~~2019~~2020 related to these actions and the status of the related accrual as of ~~September 30, 2019:~~March 31, 2020:


(in millions)
Accrued balance at December 31, 2018	$	41
Restructuring charges recorded in 2019		66
Accrued balance at December 31, 2019			$	46
Restructuring charges recorded in 2020				9
Payments and other adjustments		(45)		(18)
Accrued balance at September 30, 2019	$	62
Accrued balance at March 31, 2020			$	37

From ~~2016~~2017 to ~~2019,~~2020, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses. In the first ~~nine~~three months of ~~2019,~~2020, charges of ~~$35~~$23 million were recognized, of which ~~$10~~$1 million is recorded in Cost of products sold, $8$1 million is recorded in Research and development and ~~$17~~$21 million as Selling, general and administrative expense. The following summarizes the activity for the first ~~nine~~three months of ~~2019~~2020 related to these restructuring actions and the status of the related accrual as of ~~September 30, 2019:~~March 31, 2020:


(in millions)
Accrued balance at December 31, 2018	$	70
Restructuring charges recorded in 2019		35
Accrued balance at December 31, 2019			$	79
Restructuring charges recorded in 2020				23
Payments and other adjustments		(29)		(8)
Accrued balance at September 30, 2019	$	76
Accrued balance at March 31, 2020			$	94

Note 8 — Incentive Stock ~~Programs~~Program

In the first ~~nine~~three months of ~~2019,~~2020, Abbott granted ~~4,579,283~~3,956,637 stock options, ~~736,100~~568,471 restricted stock awards and ~~6,568,376~~5,042,550 restricted stock units under its incentive stock ~~programs.~~program. At ~~September 30, 2019,~~March 31, 2020, approximately ~~126~~112 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at ~~September 30, 2019~~March 31, 2020 is as follows:


	Outstanding		Exercisable		Outstanding		Exercisable
Number of shares		30,219,778		20,793,077		32,412,976		23,330,203
Weighted average remaining life (years)		6.5		5.5		6.5		5.5
Weighted average exercise price	$	48.65	$	41.13	$	53.83	$	44.69
Aggregate intrinsic value (in millions)	$	1,058	$	885	$	849	$	798

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2019~~

~~(Unaudited)~~

The total unrecognized share-based compensation cost at ~~September 30, 2019~~March 31, 2020 amounted to approximately ~~$501~~$687 million which is expected to be recognized over the next three years.

Note 9 — Debt and Lines of Credit

On February 24, 2019, Abbott redeemed the $500 million outstanding principal amount of its 2.80% Notes due 2020.

~~In September 2019, the board of directors authorized the early redemption of up to $5billion of outstanding long-term notes. This bond redemption authorization supersedes the board's previous authorization under which $700 million had not yet been redeemed.~~

Note 10 ~~— Leases~~

~~Leases where Abbott is the Lessee~~

Abbott has entered into operating leases as the lessee for office space, manufacturing facilities, R&D laboratories, warehouses, vehicles and equipment. Finance leases are not significant. Abbott’s operating leases generally have remaining lease terms of 1 to 10 years. Some leases include options to extend beyond the original lease term, generally up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised.

For all of its asset classes, Abbott elected the practical expedient allowed under FASB ASC No. 842, “Leases” to account for each lease component (e.g., the right to use office space) and the associated non-lease components (e.g., maintenance services) as a single lease component. Abbott also elected the short-term lease accounting policy for all asset classes; therefore, Abbott is not recognizing a lease liability or ROU asset for any lease that, at the commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset that Abbott is reasonably certain to exercise.

As Abbott’s leases typically do not provide an implicit rate, the interest rate used to determine the present value of the payments under each lease typically reflects Abbott’s incremental borrowing rate based on information available at the lease commencement date. Abbott’s incremental borrowing rates at January 1, 2019 were used for operating leases that commenced prior to January 1, 2019.

~~The following table provides information related to Abbott’s operating leases:~~

Three Months Ended

Nine Months Ended
(in millions)

September 30, 2019

September 30, 2019
Operating lease cost (a)

$
79

$
233
Cash paid for amounts included in the measurement of operating lease liabilities

$
64

$
190
ROU assets arising from entering into new operating lease obligations

$
104

$
201

~~(a)~~

~~Includes short-term lease expense and variable lease costs, which were immaterial in the three and nine months ended September 30, 2019.~~

~~The weighted average remaining lease term and discount rate for operating leases as of September 30, 2019 were 8 years and 4.1%, respectively.~~

~~Future minimum lease payments under non-cancellable operating leases as of September 30, 2019 were as follows:~~

(in millions)

2019

$
61
2020

225
2021

177
2022

137
2023

98
Thereafter

380
Total future minimum lease payments – undiscounted

1,078
Less: imputed interest

(174)
Present value of lease liabilities

$
904

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2019~~

~~(Unaudited)~~

~~The following table summarizes the amounts and location of operating lease ROU assets and lease liabilities as of September 30, 2019:~~

(in millions)

September 30, 2019

Balance Sheet Caption

Operating Lease - ROU Asset

$
881

Deferred income taxes and other assets

Operating Lease Liability:





Current

$
202

Other accrued liabilities
Non-current

702

Post-employment obligations, deferred income taxes and other long-term liabilities
Total Liability

$
904

~~Leases where Abbott is the Lessor~~

Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Operating lease revenue represented less than 3 percent of Abbott’s total net sales in the three and nine months ended September 30, 2019.

Assets related to operating leases are reported within Net property and equipment on the Condensed Consolidated Balance Sheet. The original cost and the net book value of such assets were $2.7 billion and $1.1 billion, respectively, as of September 30, 2019.

~~Note 11~~ — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange ratesprimarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling ~~$6.3~~$7.0 billion at ~~September 30, 2019~~March 31, 2020 and ~~$5.1~~$6.8 billion at December 31, ~~2018~~2019 are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value.Accumulated gains and losses as of ~~September 30, 2019 on contracts related to intercompany purchases~~March 31, 2020 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018,~~2019, Abbott held the gross notional amount of ~~$10.4~~$9.5 billion and ~~$13.6~~$9.1 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan of approximately $554 million and $546 million as of March 31, 2020 and December 31, 2019, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2020

(Unaudited)

Abbott is a party to interest rate hedge contracts totaling approximately $2.9 billion at ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018~~2019 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2019~~

~~(Unaudited)~~

The following table summarizes the amounts and location of certain derivative financial instruments as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018:~~2019:


	Fair Value - Assets					Fair Value - Liabilities					Fair Value - Assets					Fair Value - Liabilities
	Sept. 30,		Dec. 31,			Sept. 30,		Dec. 31,			March 31,		Dec. 31,			March 31,		Dec. 31,
(in millions)	2019		2018		Balance Sheet Caption	2019		2018		Balance Sheet Caption	2020		2019		Balance Sheet Caption	2020		2019		Balance Sheet Caption

Interest rate swaps designated as fair value hedges	$	74	$	—	Deferred income taxes and other assets	$	—	$	100	Post-employment obligations, deferred income taxes and other long-term liabilities	$	216	$	48	Deferred income taxes and other assets	$	—	$	—	Post-employment obligations, deferred income taxes and other long-term liabilities

Foreign currency forward exchange contracts:
Hedging instruments		244		81	Prepaid expenses and other receivables		33		44	Other accrued liabilities		247		110	Prepaid expenses and other receivables		92		56	Other accrued liabilities
Others not designated as hedges		54		33	Prepaid expenses and other receivables		62		51	Other accrued liabilities		117		38	Prepaid expenses and other receivables		97		33	Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary												—		—	n/a		554		546	Long-term debt
											$	580	$	196		$	743	$	635
	$	372	$	114		$	95	$	195

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three ~~and nine~~ months ended ~~September 30, 2019~~March 31, 2020 and ~~2018.~~2019.


	Gain (loss) Recognized in Other								Income (expense) and Gain (loss)
	Comprehensive Income (loss)								Reclassified into Income
	Three Months				Nine Months				Three Months				Nine Months					Gain (loss) Recognized in Other				Income (expense) and Gain (loss)
	Ended Sept. 30				Ended Sept. 30				Ended Sept. 30				Ended Sept. 30				Income Statement	Comprehensive Income (loss)				Reclassified into Income
(in millions)	2019		2018		2019		2018		2019		2018		2019		2018		Caption	2020		2019		2020		2019		Income Statement Caption

Foreign currency forward exchange contracts designated as cash flow hedges	$	99	$	18	$	78	$	45	$	26	$	(37)	$	58	$	(120)	Cost of products sold	$	227	$	(19)	$	11	$	15	Cost of products sold

Debt designated as a hedge of net investment in a foreign subsidiary																			(8)		—		—		—	n/a

Interest rate swaps designated as fair value hedges		n/a		n/a		n/a		n/a		35		(42)		174		(179)	Interest expense		n/a		n/a		168		43	Interest expense

~~Gains~~Losses of ~~$49~~$165 million and ~~losses~~gains of ~~$10~~$49 million were recognized in the three months ended ~~September 30,~~March 31, 2020 and 2019, and 2018, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Gains of $124 million and losses of $60 million were recognized in the nine months ended September 30, 2019 and 2018, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The hedged debt is marked to market, offsetting the effect of marking the interest rate swaps to market.

1613

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

~~September 30, 2019~~March 31, 2020

(Unaudited)

The carrying values and fair values of certain financial instruments as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018~~2019 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from ~~nonperformance~~non-performance by these counterparties.


	September 30, 2019				December 31, 2018				March 31, 2020				December 31, 2019
	Carrying		Fair		Carrying		Fair		Carrying		Fair		Carrying		Fair
(in millions)	Value		Value		Value		Value		Value		Value		Value		Value

Investment Securities:
Long-term Investment Securities:
Equity securities	$	830	$	830	$	856	$	856	$	741	$	741	$	836	$	836
Other		44		44		41		41		49		49		47		47
Total Long-term Debt		(18,893)		(21,525)		(19,366)		(19,871)		(18,068)		(20,998)		(17,938)		(20,772)
Foreign Currency Forward Exchange Contracts:
Receivable position		298		298		114		114		364		364		148		148
(Payable) position		(95)		(95)		(95)		(95)		(189)		(189)		(89)		(89)
Interest Rate Hedge Contracts:
Receivable position		74		74		—		—		216		216		48		48
(Payable) position		—		—		(100)		(100)

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:


			Basis of Fair Value Measurement								Basis of Fair Value Measurement
			Quoted		Significant						Quoted		Significant
			Prices in		Other		Significant				Prices in		Other		Significant
	Outstanding		Active		Observable		Unobservable		Outstanding		Active		Observable		Unobservable
(in millions)	Balances		Markets		Inputs		Inputs		Balances		Markets		Inputs		Inputs
September 30, 2019:
March 31, 2020:
Equity securities	$	341	$	341	$	—	$	—	$	304	$	304	$	—	$	—
Interest rate swap derivative financial instruments		74		—		74		—		216		—		216		—
Foreign currency forward exchange contracts		298		—		298		—		364		—		364		—
Total Assets	$	713	$	341	$	372	$	—	$	884	$	304	$	580	$	—

Fair value of hedged long-term debt	$	2,927	$	—	$	2,927	$	—	$	3,064	$	—	$	3,064	$	—
Foreign currency forward exchange contracts		95		—		95		—		189		—		189		—
Contingent consideration related to business combinations		68		—		—		68		67		—		—		67
Total Liabilities	$	3,090	$	—	$	3,022	$	68	$	3,320	$	—	$	3,253	$	67

December 31, 2018:
December 31, 2019:
Equity securities	$	320	$	320	$	—	$	—	$	357	$	357	$	—	$	—
Interest rate swap derivative financial instruments										48		—		48		—
Foreign currency forward exchange contracts		114		—		114		—		148		—		148		—
Total Assets	$	434	$	320	$	114	$	—	$	553	$	357	$	196	$	—

Fair value of hedged long-term debt	$	2,743	$	—	$	2,743	$	—	$	2,890	$	—	$	2,890	$	—
Interest rate swap derivative financial instruments		100		—		100		—
Foreign currency forward exchange contracts		95		—		95		—		89		—		89		—
Contingent consideration related to business combinations		71		—		—		71		68		—		—		68
Total Liabilities	$	3,009	$	—	$	2,938	$	71	$	3,047	$	—	$	2,979	$	68

The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow ~~analysis. The fair value of foreign currency forward exchange contracts is determined~~analysis using ~~a market approach, which utilizes values for comparable derivative instruments.~~significant other observable inputs. The fair value of the contingent consideration was determined based on an independent ~~appraisal~~appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.

1714

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

~~September 30, 2019~~March 31, 2020

(Unaudited)

Note 1211 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately ~~$110~~$90 million to ~~$140~~$125 million. The recorded accrual balance at ~~September 30, 2019~~March 31, 2020 for these proceedings and exposures was approximately ~~$125~~$110 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

Note 1312 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized in continuing operations for the three ~~and nine~~ months ended ~~September 30~~March 31 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:


	Defined Benefit Plans								Medical and Dental Plans								Defined Benefit Plans				Medical and Dental Plans
	Three Months				Nine Months				Three Months				Nine Months				March 31,		March 31,		March 31,		March 31,
(in millions)	Ended September 30				Ended September 30				Ended September 30				Ended September 30				2020		2019		2020		2019
	2019		2018		2019		2018		2019		2018		2019		2018
Service cost - benefits earned during the period	$	63	$	76	$	188	$	221	$	5	$	7	$	17	$	20	$	85	$	64	$	12	$	6
Interest cost on projected benefit obligations		84		77		253		232		13		12		39		36		75		84		12		13
Expected return on plan assets		(177)		(169)		(533)		(511)		(6)		(9)		(20)		(25)		(192)		(178)		(7)		(7)
Net amortization of:
Actuarial loss, net		33		51		99		154		6		8		17		25		63		33		8		6
Prior service cost (credit)		—		—		1		1		(8)		(11)		(24)		(34)		—		—		(7)		(8)
Net cost - continuing operations	$	3	$	35	$	8	$	97	$	10	$	7	$	29	$	22	$	31	$	3	$	18	$	10

Abbott funds its domestic defined benefit plans according to IRS funding limitations. International pension plans are funded according to similar regulations. In the first ~~nine~~three months of 2020 and 2019, ~~and 2018, $337~~$320 million and ~~$71~~$313 million, respectively, were contributed to defined benefit plans and $11 million was contributed to the post-employment medical and dental benefit plans in each year.

Note 1413 — Taxes on Earnings

Taxes on earnings from continuing operations reflect the estimated annual effective rates and include charges for interest and penalties. In the first ~~nine~~three months of 2020, taxes on earnings from continuing operations include approximately $47 million in excess tax benefits associated with share-based compensation. Earnings from discontinued operations, net of tax, in the first three months of 2020 reflect the recognition of $20 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years. In the first three months of 2019, taxes on earnings from continuing operations include a $78 million reduction to the transition tax related to the Tax Cut and Jobs Act (TCJA) and approximately ~~$95~~$65 million in excess tax benefits associated with share-based compensation. The $78 million reduction to the transition tax liability was the result of the issuance of final transition tax regulations by the U.S. Department of Treasury in the first quarter. This adjustment decreased the cumulative net tax expense related to the TCJA to $1.51 billion. In the first nine months of 2018, taxes on earnings from continuing operations include approximately $80 million in excess tax benefits associated with share-based compensation and a $53 million adjustment to the transition tax liability for associated effects related to state tax. Earnings from discontinued operations, net of tax, in the first nine months of 2018 reflect the recognition of $40 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years which decreased the gross amount of unrecognized tax benefits by $47 million.

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2019~~

~~(Unaudited)~~

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease between ~~$185~~$230 million and ~~$430~~$520 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., Abbott’s federal income tax returns through 2016 are settled except for the federal income tax returns of the former Alere consolidated group which are settled through ~~2014~~2015 and the former St. Jude Medical consolidated group which are settled through 2013.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2020

(Unaudited)

Note 1514 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and alternate-care testing sites. For segment reporting purposes, the Core ~~Laboratory~~Laboratories Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.

~~Cardiovascular and Neuromodulation Products~~Medical Devices — Worldwide sales of ~~cardiac~~ rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and ~~neuromodulation~~diabetes care products. For segment reporting purposes, the Cardiac ~~Arrhythmias &~~Rhythm Management, Electrophysiology and Heart Failure, Vascular, Neuromodulation, ~~and~~ Structural Heart and Diabetes Care divisions are aggregated and reported as the ~~Cardiovascular and Neuromodulation~~Medical Devices segment.

~~Non-reportable segments include Diabetes Care.~~

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

~~Table of Contents~~

~~Abbott Laboratories and Subsidiaries~~

~~Notes to the Condensed Consolidated Financial Statements~~

~~September 30, 2019~~

~~(Unaudited)~~


	Net Sales to External Customers								Operating Earnings								Three Months Ended March 31
	Three Months				Nine Months				Three Months				Nine Months				Net Sales to				Operating
	Ended September 30				Ended September 30				Ended September 30				Ended September 30				External Customers				Earnings
(in millions)	2019		2018		2019		2018		2019		2018		2019		2018		2020		2019		2020		2019
Established Pharmaceutical Products	$	1,212	$	1,159	$	3,312	$	3,332	$	281	$	289	$	654	$	664	$	1,044	$	992	$	181	$	159
Nutritional Products		1,874		1,838		5,541		5,452		414		435		1,241		1,224		1,904		1,792		459		380
Diagnostic Products		1,909		1,824		5,655		5,534		456		443		1,356		1,375		1,826		1,841		405		434
Cardiovascular and Neuromodulation Products		2,400		2,303		7,202		7,047		741		730		2,179		2,215
Medical Devices																		2,937		2,895		803		847
Total Reportable Segments		7,395		7,124		21,710		21,365		1,892		1,897		5,430		5,478		7,711		7,520		1,848		1,820
Other		681		532		1,880		1,448										15		15
Net sales	$	8,076	$	7,656	$	23,590	$	22,813									$	7,726	$	7,535
Corporate functions and benefit plan costs										(131)		(143)		(332)		(435)
Non-reportable segments										220		148		547		365
Corporate functions and benefit plans costs																						(132)		(102)
Net interest expense										(143)		(181)		(437)		(569)						(121)		(148)
Share-based compensation (a)										(94)		(83)		(434)		(396)						(233)		(226)
Amortization of intangible assets										(484)		(544)		(1,453)		(1,690)						(561)		(486)
Other, net (b)										(157)		(376)		(484)		(827)						(168)		(226)
Earnings from continuing operations before taxes									$	1,103	$	718	$	2,837	$	1,926					$	633	$	632

(a)

Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b)

Other, net includes integration costs associated with the acquisition of St. Jude Medical and Alere, and restructuring charges. Other, net for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2019 ~~and 2018~~also includes ~~restructuring charges and integration costs~~a charge associated with ~~the acquisitions of St. Jude Medical and Alere. Other, net for the nine months ended September 30, 2019 includes charges associated with~~an R&D ~~assets~~asset acquired and immediately expensed. ~~Other, net for the nine months ended September 30, 2018 includes inventory step-up amortization.~~

2016

Table of Contents

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

Financial Review - Results of Operations

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract ~~most~~ impact which products are sold; price controls, competition and rebates ~~most~~ impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are ~~nutritional products, branded generic pharmaceuticals,~~medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.

During the first quarter of 2020, the coronavirus (COVID-19) pandemic affected Abbott’s diversified health care businesses in various ways. As is further described below, some businesses faced challenges, others have been relatively stable, and still others are performing at the levels required to successfully meet new demands. Beginning in February, cardiovascular and neuromodulation ~~products.~~procedures and routine core laboratory diagnostic testing volumes declined in China as that country implemented quarantine restrictions and postponed non-emergency health care activities. As March progressed, procedures and routine testing volumes in China steadily improved from the low levels seen in February. As COVID-19 spread geographically, the impact initially expanded to certain countries in Asia and Europe beginning in late February, and more broadly across Europe and the U.S. during the last few weeks of March. As the health care industry in these countries shifted their focus to fighting COVID-19, the impact on cardiovascular and neuromodulation device procedures and routine diagnostic testing volumes was similar to what was experienced in China in February. Due to the critical nature of these products, Abbott anticipates increased demand when health care services return to more normal levels.

Abbott has mobilized its teams across multiple fronts to develop and launch three new diagnostic tests for COVID-19. In March, Abbott launched a molecular test to detect COVID-19 on its ID NOW™ rapid point-of-care platform in the U.S. pursuant to an Emergency Use Authorization (EUA). Abbott also launched a molecular test on its m2000™ RealTime lab-based platform to detect COVID-19 pursuant to an EUA in the U.S. and CE Mark. In April, Abbott launched a serology blood test on its ARCHITECT^® i1000SR and i2000SR laboratory instruments for the detection of an antibody to determine if someone was previously infected. The serology test was granted an EUA in the U.S. on April 26, 2020 and CE Mark on April 24, 2020.

Abbott is continually implementing business continuity plans in the face of the global crisis. Due to the critical nature of its products and services, Abbott is generally exempt from governmental orders in the U.S. and other countries requiring businesses to cease operations. To protect its employees, the majority of its office-based work is being conducted remotely and the company has implemented strict travel restrictions. Abbott has taken aggressive steps to limit exposure and enhance the safety of its facilities for employees working to continue to supply healthcare products to hospital and other customers.

With respect to Abbott’s financial position, at the end of the first quarter of 2020, Abbott’s cash and cash equivalents and short-term investments totaled approximately $3.7 billion and existing credit agreements are in place that would provide additional access to $5 billion, if needed.

Due to uncertainties regarding the duration and impact of the current COVID-19 pandemic, Abbott is unable to predict the extent to which the COVID-19 pandemic may have a material effect on its business, financial condition or results of operations.

Table of Contents

The following table details sales by reportable segment for the three months ~~and nine months~~ ended ~~September 30.~~March 31. Percent changes are versus the prior year and are based on unrounded numbers.

Net Sales to External Customers


Three Months

Three Months






Ended

Ended

Impact of

Total Change

September 30,

September 30,

Total

Foreign

Excl. Foreign

(in millions)

2019

2018

Change

Exchange

Exchange

Established Pharmaceutical Products

$
1,212

$
1,159

4.4
%
(3.5)
%
7.9
%
Nutritional Products

1,874

1,838

2.0

(1.3)

3.3

Diagnostic Products

1,909

1,824

4.7

(1.9)

6.6

Cardiovascular and Neuromodulation Products

2,400

2,303

4.2

(1.4)

5.6

Total Reportable Segments

7,395

7,124

3.8

(1.8)

5.6

Other

681

532

28.0

(3.5)

31.5

Net Sales

$
8,076

$
7,656

5.5

(1.9)

7.4

Total U.S.

$
2,834

$
2,707

4.7

—

4.7

Total International

$
5,242

$
4,949

5.9

(3.0)

8.9


	Net Sales to External Customers										Net Sales to External Customers
	Nine Months		Nine Months								Three Months		Three Months
	Ended		Ended				Impact of		Total Change		Ended		Ended				Impact of		Total Change
	September 30,		September 30,		Total		Foreign		Excl. Foreign		March 31,		March 31,		Total		Foreign		Excl. Foreign
(in millions)	2019		2018		Change		Exchange		Exchange		2020		2019		Change		Exchange		Exchange

Established Pharmaceutical Products	$	3,312	$	3,332	(0.6)	%	(7.1)	%	6.5	%	$	1,044	$	992	5.2	%	(4.1)	%	9.3	%
Nutritional Products		5,541		5,452	1.6		(2.8)		4.4			1,904		1,792	6.3		(1.0)		7.3
Diagnostic Products		5,655		5,534	2.2		(3.5)		5.7			1,826		1,841	(0.8)		(1.5)		0.7
Cardiovascular and Neuromodulation Products		7,202		7,047	2.2		(2.8)		5.0
Medical Devices												2,937		2,895	1.4		(1.5)		2.9
Total Reportable Segments		21,710		21,365	1.6		(3.7)		5.3			7,711		7,520	2.5		(1.8)		4.3
Other		1,880		1,448	29.9		(5.7)		35.6			15		15	5.3		(1.1)		6.4
Net Sales	$	23,590	$	22,813	3.4		(3.8)		7.2
Net sales											$	7,726	$	7,535	2.5		(1.8)		4.3

Total U.S.	$	8,438	$	8,084	4.4		—		4.4		$	2,856	$	2,754	3.7		—		3.7

Total International	$	15,152	$	14,729	2.9		(5.8)		8.7		$	4,870	$	4,781	1.8		(2.8)		4.6

Note: In order to compute results excluding the impact of foreign exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Net sales growth in ~~2019,~~2020, excluding the impact of foreign exchange, was driven by growth in ~~all of Abbott’s~~the Established Pharmaceuticals and Nutritional Products reportable segments. The increase in the Other category reflects growth in Abbott’s Diabetes Care business where sales in the first nine months of 2019 increased 30.6 percent in total and 36.5 percent, excluding the effects of foreign exchange, to $1.833 billion. The Diabetes Care sales growth was led by FreeStyle Libre^®, Abbott’s continuous glucose monitoring system with worldwide sales of $1.308 billion, which reflected an increase versus the prior year of 65.4 percent in total and 72.9 percent, excluding the effects of foreign exchange.

~~Table of Contents~~

Excluding the impact of foreign exchange, total net sales increased ~~7.4 percent in the third quarter of 2019 and 7.2~~4.3 percent in the first ~~nine months~~quarter of ~~2019.~~2020. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates ~~during~~in the ~~period compared to 2018. The~~first quarter as the relatively stronger U.S. dollar decreased total international sales by ~~3.0~~2.8 percent and total sales by ~~1.9 percent in the third quarter of 2019. The relatively stronger U.S. dollar decreased total international sales by 5.8 percent and total sales by 3.8 percent in the first nine months of 2019.~~1.8 percent.

Table of Contents

The table below provides detail by sales category for the ~~nine~~three months ended ~~September 30.~~March 31. Percent changes are versus the prior year and are based on unrounded numbers.

Impact of

Total Change

September 30,

September 30,

Total

Foreign

Excl. Foreign

(in millions)

2019

2018

Change

Exchange

Exchange

Established Pharmaceutical Products —











Key Emerging Markets

$
2,496

$
2,525

(1.2)
%
(8.6)
%
7.4
%
Other Emerging Markets

816

807

1.0

(2.7)

3.7

Nutritionals —











International Pediatric Nutritionals

1,718

1,708

0.6

(4.2)

4.8

U.S. Pediatric Nutritionals

1,406

1,376

2.2

—

2.2

International Adult Nutritionals

1,502

1,431

4.9

(5.7)

10.6

U.S. Adult Nutritionals

915

937

(2.4)

—

(2.4)

Diagnostics —











Core Laboratory

3,407

3,233

5.4

(4.6)

10.0

Molecular

326

361

(9.5)

(2.5)

(7.0)

Point of Care

424

416

2.1

(0.5)

2.6

Rapid Diagnostics

1,498

1,524

(1.7)

(2.3)

0.6

Cardiovascular and Neuromodulation —











Rhythm Management

1,600

1,667

(4.0)

(2.8)

(1.2)

Electrophysiology

1,262

1,144

10.3

(2.8)

13.1

Heart Failure

571

468

22.0

(1.5)

23.5

Vascular (a)

2,136

2,209

(3.3)

(3.0)

(0.3)

Structural Heart

1,024

913

12.1

(3.8)

15.9

Neuromodulation

609

646

(5.7)

(1.4)

(4.3)

(a) Vascular Product Lines:

Coronary and Endovascular

2,049

2,085

(1.7)

(3.1)

1.4


							Impact of		Total Change
	March 31,		March 31,		Total		Foreign		Excl. Foreign
(in millions)	2020		2019		Change		Exchange		Exchange
Established Pharmaceutical Products —
Key Emerging Markets	$	813	$	752	8.1	%	(5.0)	%	13.1	%
Other Emerging Markets		231		240	(3.7)		(1.0)		(2.7)

Nutritionals —
International Pediatric Nutritionals		571		576	(0.8)		(1.0)		0.2
U.S. Pediatric Nutritionals		518		453	14.3		—		14.3
International Adult Nutritionals		521		469	11.2		(2.6)		13.8
U.S. Adult Nutritionals		294		294	0.1		—		0.1

Diagnostics —
Core Laboratory		989		1,061	(6.8)		(1.9)		(4.9)
Molecular		139		108	29.1		(1.2)		30.3
Point of Care		138		135	2.4		(0.3)		2.7
Rapid Diagnostics		560		537	4.3		(1.1)		5.4

Medical Devices -
Rhythm Management		474		514	(7.9)		(1.4)		(6.5)
Electrophysiology		388		405	(4.0)		(1.1)		(2.9)
Heart Failure		203		184	9.9		(0.7)		10.6
Vascular (a)		625		709	(11.9)		(1.1)		(10.8)
Structural Heart		318		324	(1.8)		(1.6)		(0.2)
Neuromodulation		177		193	(8.7)		(0.9)		(7.8)
Diabetes Care		752		566	32.9		(2.7)		35.6

(a) Vascular Product Lines:
Coronary and Endovascular		603		675	(10.7)		(1.2)		(9.5)

Key Emerging Markets for the Established Pharmaceutical Products business include India, Russia, Brazil and China, along with several other markets that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets increased ~~7.4~~13.1 percent compared to the first ~~nine~~three months of ~~2018 due to~~2019 led by growth ~~across several geographies including India,~~in Russia ~~China~~ and ~~Brazil. Excluding~~various countries in Latin America and southeast Asia. Other Emerging Markets, excluding the ~~unfavorable~~ effect of foreign exchange, ~~sales in Other Emerging Markets increased 3.7~~decreased by 2.7 percent ~~compared to the first nine months of 2018. Sales growth in Other Emerging Markets was negatively impacted~~ in the first ~~nine~~three months of ~~2019 by the discontinuation of a non-core, low-margin agreement under which Abbott supplied product to a third party.~~2020.

~~The 4.8 percent increase in~~ International Pediatric Nutritional sales, excluding the effect of foreign exchange, ~~was driven by growth~~were relatively flat in the first three months of 2020 versus the comparable 2019 period. Growth across Abbott’s pediatric products in various countries in Asia and Latin America ~~across Abbott’s portfolio, including PediaSure~~^® ~~and Pedialyte~~^®~~. This growth was partially~~along with higher consumer purchases in several countries in advance of shelter in place restrictions related to the COVID-19 pandemic were offset by challenging market dynamics in the Greater China infant ~~category. In~~category, including the unfavorable impact of COVID-19. U.S.~~, the 2.2 percent increase in~~ Pediatric Nutritional sales ~~reflects growth~~increased 14.3 percent primarily due to increased demand in ~~Pedialyte and PediaSure.~~late March in advance of shelter in place restrictions related to the COVID-19 pandemic. The ~~10.6~~13.8 percent increase in International Adult Nutritional sales, excluding the effect of foreign exchange, reflects continued growth of the ~~Ensure~~Glucerna^® and ~~Glucerna~~Ensure^® brands in several countries. ~~In the~~ U.S. Adult Nutritional ~~business,~~sales were relatively flat due to the ~~decline reflects Abbott’s discontinuation~~timing of ~~a non-core product line during the third quarter of 2018.~~retailer stocking for promotional programs.

~~The 5.7~~In the Diagnostics segment, Core Laboratory sales decreased 4.9 percent, ~~increase in Diagnostic Products sales,~~ excluding the effect of foreign exchange, as the volume of routine testing performed in hospital and other laboratories was ~~driven~~negatively impacted by ~~above-market growth in Core Laboratory in~~COVID-19. In April 2020, Abbott launched a lab-based serology blood test for the ~~U.S., and internationally where Abbott is achieving continued adoption~~detection of ~~its Alinity~~^® ~~family of diagnostic instruments. In July 2019, Abbott received U.S. Food and Drug Administration (FDA) approval for its Alinity blood and plasma screening system.~~the antibody, IgG, that identifies if a person was previously infected with COVID-19. The ~~7.0~~30.3 percent ~~decrease~~increase in Molecular Diagnostics sales, excluding the effect of foreign exchange, reflects higher volumes due to the ~~negative impact~~launch in March 2020 of ~~lower non-governmental organization purchases in Africa. In March 2019, Abbott announced that it obtained CE Mark~~Abbott’s RealTime SARS-CoV-2 test for ~~its Alinity molecular diagnostics system and several testing assays.~~ use on Abbott’s m2000 RealTime System to detect COVID-19.

In Rapid Diagnostics, sales increased 5.4 percent, excluding the effect of foreign exchange, as increased testing for flu in the U.S. was partially offset by the unfavorable impact of COVID-19 on routine diagnostic testing performed in various countries outside of the U.S. In late March, Abbott launched a molecular test for the detection of COVID-19 that is run on Abbott’s point-of-care ID NOW instruments.

Excluding the effect of foreign exchange, total Medical Devices sales grew 2.9 percent; the increase was driven by double-digit growth in ~~several areas, including cardio-metabolic testing, was mostly~~Diabetes Care and Heart Failure partially offset by ~~lower than expected infectious disease testing~~the impact of the COVID-19 pandemic on Abbott’s other medical device businesses. Growth in Diabetes Care sales was driven by continued growth of FreeStyle Libre^®, Abbott’s continuous glucose monitoring system, internationally and in ~~Africa.~~the U.S. FreeStyle Libre sales totaled $604 million in the first quarter of 2020, which reflected a 62.5 percent increase, excluding the effect of foreign exchange, over the first three months of 2019 when Libre sales totaled $379 million.

2219

Table of Contents

~~Excluding the effect of foreign exchange, total Cardiovascular and Neuromodulation Products sales grew 5.0 percent; the increase was driven by double-digit growth in Electrophysiology,~~In Heart Failure, ~~and Structural Heart. The growth in Electrophysiology reflects higher~~ sales ~~of cardiac diagnostic and ablation catheters in both the U.S. and internationally. In January 2019, Abbott announced U.S. FDA approval of its TactiCath~~^® ~~contact force ablation catheter, Sensor Enabled™, which is designed to help physicians treat atrial fibrillation, a form of irregular heartbeat.~~

~~In Heart Failure,~~ growth was driven by ~~rapid~~continued market adoption ~~in the U.S.of Abbott’s~~of Abbott's HeartMate 3^® Left Ventricular Assist Device ~~following FDA approval in October 2018 as a destination (long-term use) therapy~~(LVAD) for people living with advanced heart ~~failure.~~failure as well as increased sales of Abbott’s CentriMag™ circulatory support system for use in acute hospital care. In ~~March 2019, Abbott announced new data from its MOMENTUM 3 clinical study,~~Abbott’s other cardiovascular and neuromodulation businesses, revenues were negatively impacted by reduced procedure volumes due to the largest randomized controlled trial to assess outcomes in patients receiving a heart pump to treat advanced heart failure, which demonstrated HeartMate 3 improved survival and clinical outcomes in this patient population.

~~Growth in Structural Heart was broad-based across several areas of the business, including MitraClip~~^®, Abbott's market-leading device for the minimally invasive treatment of mitral regurgitation (MR), a leaky heart valve. During the first quarter of 2019, Abbott received U.S. FDA approval for a new, expanded indication for MitraClip to treat clinically significant secondary MR as a result of underlying heart failure. This new indication expands the number of people with MR that can be treated with the MitraClip device. In July 2019, Abbott received U.S. FDA approval of the next generation of its MitraClip device, which includes a new leaflet grasping enhancement, an expanded range of clip sizes and facilitation of procedure assessment in real time to offer doctors further options when treating mitral valve disease.COVID-19 pandemic.

In ~~Vascular, excluding~~April 2017, Abbott received a warning letter from the ~~effect~~U.S. Food and Drug Administration (FDA) related to its manufacturing facility in Sylmar, CA which was acquired by Abbott on January 4, 2017 as part of ~~foreign exchange, revenues were basically flat as~~ the ~~1.4 percent increase~~acquisition of St. Jude Medical. This facility manufactures implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and monitors. Abbott prepared and executed a comprehensive plan of corrective actions. On April 28, 2020, Abbott received a letter from the FDA indicating that, based on the FDA’s evaluation, it appeared that Abbott had addressed the items in coronary and endovascular product sales, which includes drug-eluting stents, balloon catheters, guidewires, vascular imaging/diagnostics products, vessel closure, carotid and other coronary and peripheral products, was offset primarily bythe warning letter. As a ~~reduction in royalty revenue. In Rhythm Management,~~result, the 1.2 percent decline in revenues, excluding the effect of foreign exchange, reflects a 6.3 percent decrease in U.S. sales partially offset by a 4.0 percent increase in international sales. The 4.3 percent decline in Neuromodulation sales, excluding the effect of foreign exchange, reflects a 5.4 percent decline in U.S. sales.warning letter is considered closed.

The gross profit margin percentage was ~~52.4 percent for the third quarter of 2019 compared to 51.5 percent for the third quarter of 2018. The gross profit margin percentage was 52.3~~50.3 percent for the first ~~nine months~~quarter of ~~2019~~2020 compared to ~~50.9~~51.6 percent for the first ~~nine months~~quarter of ~~2018.~~2019. The ~~increase in the first nine months of 2019~~decrease primarily reflects the ~~favorable comparison versus the prior year from lower~~increase in intangible amortization expense and ~~integration and restructuring costs~~the unfavorable effect of foreign exchange on gross margin in ~~2019.~~2020.

Research and development expenses ~~increased by $22~~decreased $94 million, or ~~3.7 percent, in the third quarter of 2019 and increased by $107 million, or 6.1~~14.1 percent, in the first ~~nine months of 2019 compared to the prior year. The increase in the third~~ quarter of ~~2019 reflects higher~~2020. The 2020 decrease in R&D ~~spending in various businesses and~~expense was primarily driven by the ~~acquisition~~immediate expensing of an R&D ~~asset. The increase~~asset valued at $102 million in ~~R&D spending in the first nine months of 2019 primarily reflects higher spending on the acquisition of R&D assets. In~~ the first quarter of 2019, in conjunction with the acquisition of Cephea Valve Technologies, Inc., Abbott acquired an R&D asset valued at $102 million, which was immediately expensed. During the first nine months of 2018, Abbott acquired R&D assets valued at $43 million, which were immediately expensed. The increase in R&D expense during the first nine months of 2019 was also driven by higher R&D spending in various businesses, including Cardiovascular and Neuromodulation, partially offset by the favorable effect of foreign exchange. For the ~~nine~~three months ended ~~September 30, 2019,~~March 31, 2020, research and development expenditures totaled ~~$811~~$309 million for the ~~Cardiovascular and Neuromodulation Products~~Medical Devices segment, ~~$419~~$134 million for the Diagnostic Products segment, ~~$142~~$46 million for the Nutritional Products segment and ~~$137~~$43 million for the Established Pharmaceutical Products segment.

Selling, general and administrative (SG&A) expenses for the first quarter of 2020 increased ~~2.7~~2.8 percent ~~in the third quarter and decreased 0.4 percent in first nine months of 2019. The increase in the quarter is~~due primarily ~~due~~ to higher selling and marketing costs to drive continued growth across various businesses, partially offset by the favorable effect of foreign exchange and lower acquisition-related integration costs. The decrease in the first nine months of 2019 is due primarily to the favorable effect of foreign exchange and lower acquisition-related integration costs, partially offset by higher selling and marketing costs to drive continued growth across various businesses.

Restructuring Plans

The results for the first ~~nine~~three months of ~~2019~~2020 reflect charges under approved restructuring plans as part of the integration of the acquisitions of St. Jude Medical and Alere or as a part of various cost reduction programs. Abbott recorded employee related severance and other charges of ~~$101~~$32 million in the first ~~nine~~three months of ~~2019~~2020 related to these initiatives, of which ~~$28~~$4 million is recognized in Cost of products sold, ~~$12~~$2 million is recognized in Research and development and ~~$61~~$26 million is recognized in SG~~&A expense.~~&A. See Note 7 to the financial statements, “Restructuring Plans,” for additional information regarding these charges.

~~Table of Contents~~

Other (Income) Expense, net

Other (income) expense, net ~~totaled $55~~decreased $46 million in the first quarter of 2020 from $47 million of income in ~~the third quarter of~~ 2019 ~~compared~~ to ~~$18~~$1 million ~~of expense~~ in ~~2018 and $140 million of~~2020. The decrease in income in the first ~~nine months of 2019 compared to $93 million of income in 2018. The change in Other (income) expense, net in the third~~ quarter of ~~2019~~2020 as compared to ~~2018~~2019 was ~~primarily~~ due to ~~the recording of~~ an impairment of an investment in 2018. The increase in Other (income) expense, net in the first nine months of 2019 compared to 2018 was due to higher 2019 income related to the non-service cost component of the net periodic benefit associated with Abbott’s pension and post-retirement benefit plans and the 2018 investment impairment, partially offset by an unrealized gain on an investment in 2018 that resulted from an observable price change for a similarequity investment of ~~the same issuer.~~approximately $50 million in 2020.

Interest Expense, net

Interest expense, net decreased ~~$38 million in the third quarter of 2019 and $132~~$27 million in the first ~~nine months~~quarter of ~~2019~~2020 due to a reduction in interest expense resulting from the favorable impact of the euro debt ~~refinancing~~financing in ~~September 2018, as well as~~November of 2019 and the repayment of debt in ~~2018 and the first quarter of~~ 2019.

Taxes on Earnings ~~from Continuing Operations~~

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease between ~~$185~~$230 million and ~~$430~~$520 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., ~~Abbott’s~~Abbott's federal income tax returns through 2016 are settled except for the federal income tax returns of the former Alere consolidated group which are settled through ~~2014~~2015 and the former St. Jude Medical consolidated group which are settled through 2013.

Liquidity and Capital Resources ~~September 30, 2019~~March 31, 2020 Compared with December 31, ~~2018~~2019

The ~~$247 million increase~~reduction of cash and cash equivalents from $3.9 billion at December 31, 2019 to $3.4 billion at March 31, 2020 primarily reflects the payment of dividends and capital expenditures, partially offset by cash generated from operations in the first three months of 2020. Working capital was $4.7 billion at March 31, 2020 and $4.8 billion at December 31, 2019. The decrease in working capital in 2020 primarily reflects the decrease in cash and cash equivalents ~~from $3.8 billion at December 31, 2018 to $4.1 billion at September 30, 2019 primarily reflects the favorable impact of cash generated by operating activities,~~ partially offset by the payment of dividends, capital expenditures and the repayment of approximately $500 million of debt in the first nine months of 2019. Working capital was $5.6 billion at September 30, 2019 and December 31, 2018. In 2019, increases in inventory, accounts receivable and cash and cash equivalents were offset by an increase in ~~the current portion of long-term debt related to debt that will mature in September 2020.~~inventory.

Table of Contents

In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first ~~nine~~three months of ~~2019~~2020 totaled ~~$3.7 billion, a decrease~~$715 million, an increase of ~~$815~~$3 million over the prior year ~~due primarily to~~as the negative impact of an increased investment in working capital ~~higher~~was offset by lower cash taxes paid and ~~the timing of pension contributions in 2019 relative to 2017 and 2018, partially offset by~~ higher operating earnings. Other, net in Net cash from operating activities for the first ~~nine~~three months of ~~2019~~2020 was a use of ~~$523~~$369 million and includes ~~the impact~~$320 million of pension contributions and the payment of cash taxes of approximately ~~$775 million and $337 million of pension contributions, partially offset by payment timing for various accrued expenses.~~$125 million. Other, net in Net cash from operating activities for the first ~~nine~~three months of ~~2018~~2019 was a use of ~~$608~~$483 million and includes the favorable impact of improvements in working capital management, as well as the effect of non-cash charges related to the impairment of certain assets and the accrual of certain debt extinguishment costs. Other, net in Net cash from operating activities for the first nine months of 2018 also includes $71$313 million of pension contributions ~~as a pension contribution~~and the payment of ~~$270 million was made in December 2017. Abbott expects to fund~~ cash ~~dividends, capital expenditures and its other investments in its businesses with cash flow from operating activities, cash on hand, short-term investments and borrowings.~~taxes of approximately $185 million.

~~Table of Contents~~

In September 2019, the board of directors authorized the early redemption of up to $5 billion of outstanding long-term notes. This bond redemption authorization ~~supersedes~~superseded the board’s previous authorization under which $700 million had not yet been redeemed. In December 2019, Abbott redeemed $2.850 billion of debt. After this redemption, $2.15 billion of the $5 billion debt redemption authorization remains available.

At ~~September 30, 2019,~~March 31, 2020, Abbott’s long-term debt rating was ~~BBB+~~A- by Standard & Poor’s Corporation and A3 by Moody’s Investors Service. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources, including lines of credit of $5.0 billion which expire in 2023.

In October 2019, the board of directors authorized the repurchase of up to $3 billion of Abbott’s common shares from time to time. The new authorization is in addition to the ~~$795~~$270 million unused portion of the ~~previous~~ share repurchase program ~~that was~~ authorized in ~~September~~ 2014.

On April 27, 2016, the board of directors authorized the issuance and sale for general corporate purposes of up to 75 million common shares that would result in proceeds of up to $3 ~~billion of common shares for general corporate purposes.~~billion. No shares have been issued under this authorization.

In ~~each of~~ the first ~~three quarters~~quarter of ~~2019,~~2020, Abbott declared a quarterly dividend of ~~$0.32~~$0.36 per share on its common shares, which represents an increase of approximately 1412.5 percent over the ~~$0.28~~$0.32 per share ~~quarterly~~ dividend declared in ~~each of~~ the first ~~three quarters~~quarter of ~~2018.~~2019.

Recently ~~Issued~~Adopted Accounting Standards ~~Not Yet Adopted~~

In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments – Credit Losses,which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. The new standard will be effective for Abbott at the beginning of 2020, with early adoption permitted. Abbott is currently assessing the impact of this new standard on its consolidated financial statements.

~~Lease Accounting Standard~~

~~In February 2016, the FASB issued ASU 2016-02,~~ ~~Leases~~~~, which requires lessees to measure and recognize a lease asset and liability on the balance sheet for most leases, including operating leases.~~ Abbott adopted the ~~new~~ standard ~~as of~~on January 1, ~~2019 using the modified retrospective approach~~2020 and ~~applied the standard’s transition provisions as of January 1, 2019. As~~recorded a ~~result, no changes were made~~cumulative adjustment that was not significant to the December 31, 2018 Consolidated Balance Sheet. Abbott elected to apply the package of practical expedients related to transition. These practical expedients allowed Abbott to carry forward its historical assessments of whether any existing contracts are or contain leases, the lease classification for each lease existing at January 1, 2019, and whether any initial direct costs for such leases qualified for capitalization.

~~The new lease accounting standard does not have a material impact on the amounts reported~~Earnings employed in the ~~Condensed Consolidated Statement of Earnings but does have a material impact on the amounts reported~~business in the Condensed Consolidated Balance Sheet. ~~Adoption~~

Recently Issued Accounting Standards Not Yet Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard becomes effective for Abbott in the first quarter of 2021 and early adoption is permitted. Abbott does not expect adoption of this new standard ~~resulted in the recording of approximately $850 million of new right of use (ROU) assets and additional liabilities for operating leases~~to have a material impact on ~~the Condensed Consolidated Balance Sheet as of January 1, 2019.~~its condensed consolidated financial statements.

Legislative Issues

Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the ~~2018~~2019 Annual Report on Form 10-K.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions ~~investors~~ that any forward-looking statements ~~or projections~~ made by Abbott ~~including those made in this document,~~ are subject to risks and uncertainties, including the impact of the COVID-19 pandemic on Abbott's operations and financial results, that may cause actual results to differ materially from those ~~projected.~~indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect ~~Abbott’s~~Abbott's operations are discussed in Item 1A, ~~Risk Factors,~~"Risk Factors'', in the ~~2018~~2019 Annual Report on Form ~~10-K.~~10-K and in Item 1A, “Risk Factors”, in the quarterly report for the quarter ended March 31, 2020. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

2521

Table of Contents

PART I. FINANCIAL INFORMATION

Item 4.Controls and Procedures

~~(a)~~~~Evaluation of disclosure controls and procedures.~~ The Chief Executive Officer, Miles D. White, and Chief Financial Officer, Brian B. Yoor, evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(a)

Evaluation of disclosure controls and procedures. The President and Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Robert E. Funck, Jr., evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

~~(b)~~~~Changes in internal control over financial reporting.~~ During the quarter ended September 30, 2019, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

(b)

Changes in internal control over financial reporting. During the quarter ended March 31, 2020, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations, including those described in our Annual Report on Form 10-K for the year ended December 31, ~~2018.~~2019.

Item 1A. Risk Factors

There have been no material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019, except for the following:

Abbott is subject to risks related to public health crises, such as widespread outbreaks of infectious diseases like the COVID-19 pandemic.

As a global healthcare company, public health crises, such as the widespread outbreaks of infectious diseases like the COVID-19 pandemic, may negatively impact Abbott's operations. Health concerns and significant changes in political or economic conditions caused by such outbreaks can cause significant reductions in demand for routine diagnostic testing and medical device procedures or increased difficulty in serving customers, disrupt manufacturing and supply chains, and negatively affect our operations as well as the operations of our suppliers, distributors and other third-party partners. Furthermore, such widespread outbreaks may impact the broader economies of affected countries, including negatively impacting economic growth, the proper functioning of financial and capital markets, foreign currency exchange rates, and interest rates. Due to uncertainties regarding the duration and impact of the current COVID-19 pandemic, Abbott is unable to predict the extent to which the COVID-19 pandemic may have a material effect on its business, financial condition or results of operations.

2622

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(c)Issuer Purchases of Equity Securities

(d) Maximum

Number (or

(c) Total Number

Approximate

(c) Total Number

Approximate

of Shares (or

Dollar Value) of

of Shares (or

Dollar Value) of

(a) Total

Units) Purchased

Shares (or Units)

(a) Total

Units) Purchased

Shares (or Units)

Number of

(b) Average

as Part of

that May Yet Be

Number of

(b) Average

as Part of

that May Yet Be

Shares (or

Price Paid per

Publicly

Purchased Under

Shares (or

Price Paid per

Publicly

Purchased Under

Units)

Share (or

Announced Plans

the Plans or

Units)

Share (or

Announced Plans

the Plans or

Period

Purchased

Unit)

or Programs

Programs

Purchased

Unit)

or Programs

Programs

July 1, 2019 - July 31, 2019

294

⁽¹⁾

88.740

795,235,049

⁽²⁾

August 1, 2019 - August 31, 2019

28,134

⁽¹⁾

85.134

795,235,049

⁽²⁾

September 1, 2019 - September 30, 2019

11,800

⁽¹⁾

83.354

795,235,049

⁽²⁾

January 1, 2020 - January 31, 2020

2,957

⁽¹⁾

85.89

3,270,234,923

⁽²⁾

February 1, 2020 - February 29, 2020

⁽¹⁾

3,270,234,923

⁽²⁾

March 1, 2020 - March 31, 2020

⁽¹⁾

3,270,234,923

⁽²⁾

Total

40,228

⁽¹⁾

84.638

795,235,049

⁽²⁾

2,957

⁽¹⁾

85.89

3,270,234,923

⁽²⁾

1.	~~These shares include:~~

(1) These shares include the shares deemed surrendered to Abbott to pay the exercise price in connection with the exercise of employee stock options – 2,957 in January, 0 in February, and 0 in March.

~~(i)~~

~~the shares deemed surrendered to Abbott to pay the exercise price in connection with the exercise of employee stock options – 294 in July, 16,334 in August, and 0 in September; and~~

~~(ii)~~

~~the shares purchased on the open market for the benefit of participants in the Abbott Laboratories, Limited Employee Stock Purchase Plan – 0 in July, 11,800 in August, and 11,800 in September.~~

These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

On September 11, 2014, the board of directors authorized the repurchase of up to $3 billion of Abbott common shares, from time to time (the “2014 Plan”). On October 11, 2019, the board of directors authorized the repurchase of up to $3 billion of Abbott common shares, from time to time (the “2019 Plan”). The 2019 Plan is in addition to the unused portion of the 2014 Plan.

(2) On September 11, 2014, the board of directors authorized the repurchase of up to $3 billion of Abbott common shares, from time to time (the “2014 Plan”). On October 11, 2019, the board of directors authorized the repurchase of up to $3 billion of Abbott common shares, from time to time (the “2019 Plan”). The 2019 Plan is in addition to the unused portion of the 2014 Plan.

2723

Table of Contents

Item 6. Exhibits


Exhibit No.		Exhibit

3.1		By-Laws of Abbott Laboratories, as amended and restated, effective ~~September 9, 2019,~~April 24, 2020, filed as Exhibit 3.1 to the Abbott Laboratories Current Report on Form 8-K filed on ~~September 10, 2019.~~February 27, 2020.

31.1		Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

31.2		Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.

32.1		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter ~~and nine months~~ ended ~~September 30, 2019,~~March 31, 2020, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Shareholders' Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements.

104		Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101).

2824

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


ABBOTT LABORATORIES


By:	/s/ ~~Brian B. Yoor~~Robert E. Funck, Jr.
	~~Brian B. Yoor~~Robert E. Funck, Jr.
	Executive Vice President, Finance and Chief Financial Officer

	Date: ~~October 31, 2019~~April 29, 2020

2925


	Nine Months Ended September 30, 2019						Nine Months Ended September 30, 2018
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	2,496	$	2,496	$	—	$	2,525	$	2,525
Other		—		816		816		—		807		807
Total		—		3,312		3,312		—		3,332		3,332

Nutritionals —
Pediatric Nutritionals		1,406		1,718		3,124		1,376		1,708		3,084
Adult Nutritionals		915		1,502		2,417		937		1,431		2,368
Total		2,321		3,220		5,541		2,313		3,139		5,452

Diagnostics —
Core Laboratory		793		2,614		3,407		725		2,508		3,233
Molecular		113		213		326		114		247		361
Point of Care		334		90		424		324		92		416
Rapid Diagnostics		881		617		1,498		855		669		1,524
Total		2,121		3,534		5,655		2,018		3,516		5,534

Cardiovascular and Neuromodulation —
Rhythm Management		790		810		1,600		843		824		1,667
Electrophysiology		549		713		1,262		499		645		1,144
Heart Failure		428		143		571		342		126		468
Vascular		787		1,349		2,136		854		1,355		2,209
Structural Heart		446		578		1,024		353		560		913
Neuromodulation		485		124		609		513		133		646
Total		3,485		3,717		7,202		3,404		3,643		7,047

Other		511		1,369		1,880		349		1,099		1,448
Total	$	8,438	$	15,152	$	23,590	$	8,084	$	14,729	$	22,813


(in millions)
Contract Liabilities:
Balance at December 31, 2018	$	259
Unearned revenue from cash received during the period		285
Revenue recognized that was included in contract liability balance at beginning of period		(249)
Balance at September 30, 2019	$	295


	Three Months Ended		Nine Months Ended
(in millions)	September 30, 2019		September 30, 2019
Operating lease cost (a)	$	79	$	233
Cash paid for amounts included in the measurement of operating lease liabilities	$	64	$	190
ROU assets arising from entering into new operating lease obligations	$	104	$	201


(in millions)
2019	$	61
2020		225
2021		177
2022		137
2023		98
Thereafter		380
Total future minimum lease payments – undiscounted		1,078
Less: imputed interest		(174)
Present value of lease liabilities	$	904